Century Therapeutics, Inc.

NASDAQ:IPSC

Biotechnology

Healthcare
$1.32 +0.48%

+$0.01 today

Market cap
$239.71M
Beta
1.57
P/E (TTM)
-1.8
EPS (TTM)
-$1.25
52W Low $0.44High $3.04

Volume 0.82M

Average 1.12M

Returns on capital

Century Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-6.0%

avg 13.0%

ROIC

-7.2%

avg -33.7%

ROA

-4.3%

avg -63.8%

Analysis

ROA is currently the strongest return metric at -4.3% versus its period average of -63.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Brent Pfeiffenberger

President, Chief Executive Officer & ChairmanUSD 971.73K483.63M4.20%

Gregory Russotti

Chief Technology & Manufacturing OfficerUSD 789.96K59509.20K0.59%

Chad A. Cowan

Chief Scientific OfficerUSD 760.54K54——

Krista Kauppinen

VP, General Counsel & Head of Intellectual Property————

Michael Naso

Senior Vice President of Cell Engineering————

Megan Bilson

Chief People Officer————

Douglas Carr

Senior VP of Finance & Operations, Principal Financial Officer and Secretary——502.64K0.58%

Elizabeth Devlin

Vice President & Head of Development————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 3, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$79,604.70

Sells

19

$71,684.01

Net Transaction Value

+$7,920.68

Net buying

Most Active

Carr Douglas

11 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 3, 26

Carr Douglas

Direct

Sell$404.1
Sep 14, 26

Russotti Gregory

Direct

Sell$5K
Sep 14, 26

Carr Douglas

Direct

Sell$3.2K
Sep 8, 26

Russotti Gregory

Direct

Sell$1.1K
Sep 8, 26

Carr Douglas

Direct

Sell$520.7
Aug 3, 26

Carr Douglas

Direct

Sell$543.7
Jun 12, 26

Carr Douglas

Direct

Sell$3.7K
Jun 12, 26

Russotti Gregory

Direct

Sell$5.8K
Jun 8, 26

Russotti Gregory

Direct

Sell$1.1K
Jun 8, 26

Carr Douglas

Direct

Sell$525.6

1–10 of 21

Summary

Insiders reported 2 buys worth $79,604.70 and 19 sells worth $71,684.01 over the last 12 months. That adds up to net buying of $7,920.68. Carr Douglas was the most active insider with 11 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+175.9%
-17.0% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +175.9% over three years. Forward estimates point to Revenue at -17.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Century Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IPSC's management, answered from reported figures.

Who manages IPSC?

Century Therapeutics, Inc. (IPSC) lists 8 active executives. The top listed executive is Chad A. Cowan, Chief Scientific Officer.

Are IPSC insiders buying or selling?

Recent insider activity shows net buying of $17.81M.